Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Okta, Inc. (“Okta” or the “Company”) (NASDAQ: OKTA) and certain of its...
-
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- omerantz LLP announces that a class action lawsuit has been filed against Enservco Corporation (“Enservco” or the “Company”) (NYSE: ENSV) and certain of...
-
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR) and certain of its...
-
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Digital Turbine, Inc. (“Digital Turbine” or the “Company”) (NASDAQ: APPS). Such investors...
-
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Carvana Co. (“Carvana” or the “Company”) (NYSE: CVNA). Such investors are advised to...
-
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allianz SE (“Allianz” or the “Company”) (OTCMKTS: ALIZF). Such investors are advised to...
-
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arqit Quantum Inc. (f/k/a Centricus Acquisition Corp.) (“Arqit” or the “Company”) (NASDAQ:...
-
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eliem Therapeutics, Inc. (“Eliem” or the “Company”) (NASDAQ: ELYM). Such investors are...
-
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are...
-
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ: MOLN). Such...